December 10, 2025 · Form 4 insider transaction
HILLHOUSE INVESTMENT MANAGEMENT, LTD. sold 555,555 shares of ArriVent BioPharma, Inc. at $23.37 per share, a transaction worth $12.98M. The trade was recorded as open-market sale and disclosed on an SEC Form 4, filed 55 days after the transaction.
The securities reported herein were held by HACF, L.P., an exempted Cayman Islands limited partnership ("HACF"). HHLR (as defined below) acts as the sole management company of HACF.; The securities reported herein are held by VSUM VI Holdings Limited ("VSUM VI"), VSUM VIII Holdings Limited ("VSUM VIII") and ARVT Holdings Limited ("ARVT"). VSUM VI is a wholly owned subsidiary of Hillhouse Venture Fund V, L.P. ("Venture Fund V"), VSUM VIII is a wholly owned subsidiary of Hillhouse Healthcare Fund, L.P. ("Healthcare Fund") and ARVT is a wholly owned subsidiary of Hillhouse Venture Fund VI, L.P. ("Venture Fund VI"). HIM (as defined below) acts as the sole management company of each of Venture Fund V, Healthcare Fund and Venture Fund VI.; This statement is filed by (i) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM") and (ii) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HIM and HHLR are under common control and share certain policies, personnel and resources. Accordingly, HIM and HHLR are filing this Form 4 jointly.; The filing of this statement shall not be deemed an admission that each of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.